Zomepirac

Zomepirac is a nonsteroidal anti-inflammatory drug (NSAID) that was introduced in the early 1980s under the brand name Zomax. It was primarily used for its analgesic properties to relieve moderate to severe pain. Despite its effectiveness, the use of Zomepirac was associated with serious adverse effects, leading to its withdrawal from the market.

Pharmacology

Zomepirac functions by inhibiting the enzyme cyclooxygenase (COX), which is essential in the biosynthesis of prostaglandins. Prostaglandins are lipid compounds that play a key role in inflammation, pain, and fever. By reducing the production of prostaglandins, Zomepirac effectively alleviates pain and reduces inflammation.

Clinical Use

Zomepirac was indicated for the management of acute pain conditions. Its potency and ability to provide significant pain relief made it a popular choice for post-operative pain, as well as for conditions such as arthritis and other musculoskeletal disorders.

Adverse Effects

The use of Zomepirac was associated with several adverse effects, the most serious being an increased risk of anaphylaxis. Anaphylaxis is a severe, potentially life-threatening allergic reaction that can occur rapidly. Other side effects included gastrointestinal issues, such as ulcers and bleeding, as well as renal impairment.

Market Withdrawal

Due to the risk of severe allergic reactions, Zomepirac was withdrawn from the market in 1983. The decision to remove the drug was based on the accumulation of reports indicating a higher than acceptable risk of anaphylaxis among users. The withdrawal of Zomepirac highlights the importance of post-marketing surveillance in the pharmaceutical industry, ensuring that the benefits of a drug outweigh its risks.

Legacy

The withdrawal of Zomepirac serves as a case study in drug safety and pharmacovigilance. It underscores the necessity for ongoing monitoring of drugs after they have been approved and introduced to the market. The case of Zomepirac also emphasizes the importance of patient education regarding the potential risks associated with medication use.

See Also

• Nonsteroidal anti-inflammatory drug
• Cyclooxygenase
• Prostaglandin
• Anaphylaxis
• Pharmacovigilance

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian